1. Home
  2. PCVX vs BIO Comparison

PCVX vs BIO Comparison

Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • BIO
  • Stock Information
  • Founded
  • PCVX 2013
  • BIO 1952
  • Country
  • PCVX United States
  • BIO United States
  • Employees
  • PCVX N/A
  • BIO N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • PCVX Health Care
  • BIO Industrials
  • Exchange
  • PCVX Nasdaq
  • BIO Nasdaq
  • Market Cap
  • PCVX 6.0B
  • BIO 8.2B
  • IPO Year
  • PCVX 2020
  • BIO N/A
  • Fundamental
  • Price
  • PCVX $49.61
  • BIO $329.55
  • Analyst Decision
  • PCVX Strong Buy
  • BIO Strong Buy
  • Analyst Count
  • PCVX 7
  • BIO 4
  • Target Price
  • PCVX $101.67
  • BIO $358.50
  • AVG Volume (30 Days)
  • PCVX 1.4M
  • BIO 213.1K
  • Earning Date
  • PCVX 11-04-2025
  • BIO 10-29-2025
  • Dividend Yield
  • PCVX N/A
  • BIO N/A
  • EPS Growth
  • PCVX N/A
  • BIO N/A
  • EPS
  • PCVX N/A
  • BIO N/A
  • Revenue
  • PCVX N/A
  • BIO $2,557,500,000.00
  • Revenue This Year
  • PCVX N/A
  • BIO $1.89
  • Revenue Next Year
  • PCVX N/A
  • BIO $2.45
  • P/E Ratio
  • PCVX N/A
  • BIO N/A
  • Revenue Growth
  • PCVX N/A
  • BIO N/A
  • 52 Week Low
  • PCVX $27.66
  • BIO $211.43
  • 52 Week High
  • PCVX $94.76
  • BIO $373.69
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 65.00
  • BIO 59.03
  • Support Level
  • PCVX $47.02
  • BIO $298.35
  • Resistance Level
  • PCVX $50.27
  • BIO $334.53
  • Average True Range (ATR)
  • PCVX 2.12
  • BIO 11.15
  • MACD
  • PCVX 0.20
  • BIO 1.41
  • Stochastic Oscillator
  • PCVX 93.34
  • BIO 85.38

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: